{
  "success": true,
  "pagesUsed": [
    7,
    14,
    19
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "Title Page",
        "text": "Title Page",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.0",
        "sectionTitle": "Title Page",
        "sectionType": {
          "id": "0d2bbf85-28d7-47c2-a16c-90d4a1678d29",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "Protocol Amendment: Summary of Changes",
        "text": "Protocol Amendment: Summary of Changes",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.1",
        "sectionTitle": "Protocol Amendment: Summary of Changes",
        "sectionType": {
          "id": "86166fc2-f2bf-42ef-94e8-d5bb59df903e",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "Synopsis",
        "text": "Synopsis",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.2",
        "sectionTitle": "Synopsis",
        "sectionType": {
          "id": "32e6bc46-7107-4d1e-a1ec-bc914735242b",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "List of Abbreviations and Definition of Terms",
        "text": "List of Abbreviations and Definition of Terms",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1.3",
        "sectionTitle": "List of Abbreviations and Definition of Terms",
        "sectionType": {
          "id": "3118a4d0-3514-43e9-9bb1-d1e4d7b6e4e8",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_5",
        "name": "Table of Contents",
        "text": "Table of Contents",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2.0",
        "sectionTitle": "Table of Contents",
        "sectionType": {
          "id": "79cc4dcb-55ae-4be5-89f4-4f1f0a330dff",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_6",
        "name": "Introduction",
        "text": "Introduction",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3.0",
        "sectionTitle": "Introduction",
        "sectionType": {
          "id": "c22f4fcd-917b-4493-933e-1e49d051e160",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "Study Objective",
        "text": "Study Objective",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4.0",
        "sectionTitle": "Study Objective",
        "sectionType": {
          "id": "4e205225-ec05-4d12-8eea-3977430bb190",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "Investigational Plan",
        "text": "Investigational Plan",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5.0",
        "sectionTitle": "Investigational Plan",
        "sectionType": {
          "id": "d9560f2c-34d1-4d6f-a65a-353044443cab",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2",
          "nci_8_3",
          "nci_8_4",
          "nci_8_5",
          "nci_8_6",
          "nci_8_7",
          "nci_8_8",
          "nci_8_9",
          "nci_8_10",
          "nci_8_11",
          "nci_8_12",
          "nci_8_13",
          "nci_8_14",
          "nci_8_15",
          "nci_8_16",
          "nci_8_17",
          "nci_8_18",
          "nci_8_19",
          "nci_8_20"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_6_1",
        "name": "Differences Statement",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Differences Statement"
      },
      {
        "id": "nci_6_2",
        "name": "Benefits and Risks",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Benefits and Risks"
      },
      {
        "id": "nci_8_1",
        "name": "Overall Study Design and Plan: Description",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.1",
        "sectionTitle": "Overall Study Design and Plan: Description"
      },
      {
        "id": "nci_8_2",
        "name": "Selection of Study Population",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2",
        "sectionTitle": "Selection of Study Population"
      },
      {
        "id": "nci_8_3",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_8_4",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_8_5",
        "name": "Prior, Concomitant, and Prohibited Therapy",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3",
        "sectionTitle": "Prior, Concomitant, and Prohibited Therapy"
      },
      {
        "id": "nci_8_6",
        "name": "Prior Therapy",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.1",
        "sectionTitle": "Prior Therapy"
      },
      {
        "id": "nci_8_7",
        "name": "Permitted Background Therapy",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.2",
        "sectionTitle": "Permitted Background Therapy"
      },
      {
        "id": "nci_8_8",
        "name": "Prohibited Therapy",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.3",
        "sectionTitle": "Prohibited Therapy"
      },
      {
        "id": "nci_8_9",
        "name": "Rescue Therapy",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.3.4",
        "sectionTitle": "Rescue Therapy"
      },
      {
        "id": "nci_8_10",
        "name": "Contraception Recommendations",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2.4",
        "sectionTitle": "Contraception Recommendations"
      },
      {
        "id": "nci_8_11",
        "name": "Efficacy and Safety Assessments/Variables",
        "text": "",
        "order": 10,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3",
        "sectionTitle": "Efficacy and Safety Assessments/Variables"
      },
      {
        "id": "nci_8_12",
        "name": "Efficacy and Safety Measurements Assessed",
        "text": "",
        "order": 11,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1",
        "sectionTitle": "Efficacy and Safety Measurements Assessed"
      },
      {
        "id": "nci_8_13",
        "name": "Study Procedures",
        "text": "",
        "order": 12,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1.1",
        "sectionTitle": "Study Procedures"
      },
      {
        "id": "nci_8_14",
        "name": "Optional Samples for Exploratory Research and Validation Studies",
        "text": "",
        "order": 13,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.1.2",
        "sectionTitle": "Optional Samples for Exploratory Research and Validation Studies"
      },
      {
        "id": "nci_8_15",
        "name": "Drug Concentration Measurements",
        "text": "",
        "order": 14,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.2",
        "sectionTitle": "Drug Concentration Measurements"
      },
      {
        "id": "nci_8_16",
        "name": "Measurement Methods",
        "text": "",
        "order": 15,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.2.1",
        "sectionTitle": "Measurement Methods"
      },
      {
        "id": "nci_8_17",
        "name": "Efficacy Variables",
        "text": "",
        "order": 16,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3",
        "sectionTitle": "Efficacy Variables"
      },
      {
        "id": "nci_8_18",
        "name": "Primary Variables",
        "text": "",
        "order": 17,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3.1",
        "sectionTitle": "Primary Variables"
      },
      {
        "id": "nci_8_19",
        "name": "Key Secondary Variables",
        "text": "",
        "order": 18,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3.2",
        "sectionTitle": "Key Secondary Variables"
      },
      {
        "id": "nci_8_20",
        "name": "Additional Variables",
        "text": "",
        "order": 19,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3.3.3",
        "sectionTitle": "Additional Variables"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "QD",
        "expandedText": "once daily",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "PsA",
        "expandedText": "Psoriatic Arthritis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "bDMARD",
        "expandedText": "Biologic Disease Modifying Anti-Rheumatic Drug",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "Bio-IR",
        "expandedText": "inadequate response to bDMARDs",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "ACR",
        "expandedText": "American College of Rheumatology",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "ADL",
        "expandedText": "Activities of Daily Living",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "AE",
        "expandedText": "Adverse Event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "AESI",
        "expandedText": "Adverse Events of Special Interest",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "ALC",
        "expandedText": "Absolute Lymphocyte Count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "ALT",
        "expandedText": "ALT",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "ANC",
        "expandedText": "Absolute Neutrophil Count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "Anti-CCP",
        "expandedText": "Anti-Cyclic Citrullinated Peptide",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "ASDAS",
        "expandedText": "Ankylosing Spondylitis Disease Activity Score",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "AST",
        "expandedText": "Aspartate Transaminase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "AUC",
        "expandedText": "Area under the plasma concentration-time curve",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "BASDAI",
        "expandedText": "Bath Ankylosing Spondylitis Disease Activity Index",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "BCG",
        "expandedText": "Bacillus Calmette-Guerin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "BSA",
        "expandedText": "Body Surface Area",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "BUN",
        "expandedText": "Blood Urea Nitrogen",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "CASPAR",
        "expandedText": "Classification Criteria for Psoriatic Arthritis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "CBC",
        "expandedText": "Complete Blood Count",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "CCP",
        "expandedText": "Cyclic Citrullinated Peptide",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "CDAI",
        "expandedText": "Clinical Disease Activity Index",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "CL/F",
        "expandedText": "Apparent Clearance",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "Cmax",
        "expandedText": "Maximum Observed Plasma Concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "Cmin",
        "expandedText": "Minimum Observed Plasma Concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "COVID-19",
        "expandedText": "Coronavirus Disease – 2019",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "CRF",
        "expandedText": "Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "CS",
        "expandedText": "Clinically Significant",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "csDMARD",
        "expandedText": "Conventionally synthetic Disease Modifying Anti-Rheumatic Drug",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "CTCAE",
        "expandedText": "Common Terminology Criteria for Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "CXR",
        "expandedText": "Chest X-Ray",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "CYP3A",
        "expandedText": "Cytochrome P450 3A",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 8,
      "itemCount": 22,
      "abbreviationCount": 34
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) – SELECT – PsA 2",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment 8",
      "versionDate": "29 January 2021",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "QD",
          "expansion": "once daily"
        },
        {
          "abbreviation": "PsA",
          "expansion": "Psoriatic Arthritis"
        },
        {
          "abbreviation": "bDMARD",
          "expansion": "Biologic Disease Modifying Anti-Rheumatic Drug"
        },
        {
          "abbreviation": "Bio-IR",
          "expansion": "inadequate response to bDMARDs"
        },
        {
          "abbreviation": "ACR",
          "expansion": "American College of Rheumatology"
        },
        {
          "abbreviation": "ADL",
          "expansion": "Activities of Daily Living"
        },
        {
          "abbreviation": "AE",
          "expansion": "Adverse Event"
        },
        {
          "abbreviation": "AESI",
          "expansion": "Adverse Events of Special Interest"
        },
        {
          "abbreviation": "ALC",
          "expansion": "Absolute Lymphocyte Count"
        },
        {
          "abbreviation": "ALT",
          "expansion": "ALT"
        },
        {
          "abbreviation": "ANC",
          "expansion": "Absolute Neutrophil Count"
        },
        {
          "abbreviation": "Anti-CCP",
          "expansion": "Anti-Cyclic Citrullinated Peptide"
        },
        {
          "abbreviation": "ASDAS",
          "expansion": "Ankylosing Spondylitis Disease Activity Score"
        },
        {
          "abbreviation": "AST",
          "expansion": "Aspartate Transaminase"
        },
        {
          "abbreviation": "AUC",
          "expansion": "Area under the plasma concentration-time curve"
        },
        {
          "abbreviation": "BASDAI",
          "expansion": "Bath Ankylosing Spondylitis Disease Activity Index"
        },
        {
          "abbreviation": "BCG",
          "expansion": "Bacillus Calmette-Guerin"
        },
        {
          "abbreviation": "BSA",
          "expansion": "Body Surface Area"
        },
        {
          "abbreviation": "BUN",
          "expansion": "Blood Urea Nitrogen"
        },
        {
          "abbreviation": "CASPAR",
          "expansion": "Classification Criteria for Psoriatic Arthritis"
        },
        {
          "abbreviation": "CBC",
          "expansion": "Complete Blood Count"
        },
        {
          "abbreviation": "CCP",
          "expansion": "Cyclic Citrullinated Peptide"
        },
        {
          "abbreviation": "CDAI",
          "expansion": "Clinical Disease Activity Index"
        },
        {
          "abbreviation": "CL/F",
          "expansion": "Apparent Clearance"
        },
        {
          "abbreviation": "Cmax",
          "expansion": "Maximum Observed Plasma Concentration"
        },
        {
          "abbreviation": "Cmin",
          "expansion": "Minimum Observed Plasma Concentration"
        },
        {
          "abbreviation": "COVID-19",
          "expansion": "Coronavirus Disease – 2019"
        },
        {
          "abbreviation": "CRF",
          "expansion": "Case Report Form"
        },
        {
          "abbreviation": "CS",
          "expansion": "Clinically Significant"
        },
        {
          "abbreviation": "csDMARD",
          "expansion": "Conventionally synthetic Disease Modifying Anti-Rheumatic Drug"
        },
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "CTCAE",
          "expansion": "Common Terminology Criteria for Adverse Events"
        },
        {
          "abbreviation": "CXR",
          "expansion": "Chest X-Ray"
        },
        {
          "abbreviation": "CYP3A",
          "expansion": "Cytochrome P450 3A"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) – SELECT – PsA 2",
        "version": "Amendment 8",
        "versionDate": "29 January 2021"
      },
      "sections": [
        {
          "number": "1.0",
          "title": "Title Page",
          "type": "Other"
        },
        {
          "number": "1.1",
          "title": "Protocol Amendment: Summary of Changes",
          "type": "Other"
        },
        {
          "number": "1.2",
          "title": "Synopsis",
          "type": "Synopsis"
        },
        {
          "number": "1.3",
          "title": "List of Abbreviations and Definition of Terms",
          "type": "Other"
        },
        {
          "number": "2.0",
          "title": "Table of Contents",
          "type": "Other"
        },
        {
          "number": "3.0",
          "title": "Introduction",
          "type": "Introduction",
          "subsections": [
            {
              "number": "3.1",
              "title": "Differences Statement"
            },
            {
              "number": "3.2",
              "title": "Benefits and Risks"
            }
          ]
        },
        {
          "number": "4.0",
          "title": "Study Objective",
          "type": "Objectives"
        },
        {
          "number": "5.0",
          "title": "Investigational Plan",
          "type": "Study Design",
          "subsections": [
            {
              "number": "5.1",
              "title": "Overall Study Design and Plan: Description"
            },
            {
              "number": "5.2",
              "title": "Selection of Study Population"
            },
            {
              "number": "5.2.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "5.2.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "5.2.3",
              "title": "Prior, Concomitant, and Prohibited Therapy"
            },
            {
              "number": "5.2.3.1",
              "title": "Prior Therapy"
            },
            {
              "number": "5.2.3.2",
              "title": "Permitted Background Therapy"
            },
            {
              "number": "5.2.3.3",
              "title": "Prohibited Therapy"
            },
            {
              "number": "5.2.3.4",
              "title": "Rescue Therapy"
            },
            {
              "number": "5.2.4",
              "title": "Contraception Recommendations"
            },
            {
              "number": "5.3",
              "title": "Efficacy and Safety Assessments/Variables"
            },
            {
              "number": "5.3.1",
              "title": "Efficacy and Safety Measurements Assessed"
            },
            {
              "number": "5.3.1.1",
              "title": "Study Procedures"
            },
            {
              "number": "5.3.1.2",
              "title": "Optional Samples for Exploratory Research and Validation Studies"
            },
            {
              "number": "5.3.2",
              "title": "Drug Concentration Measurements"
            },
            {
              "number": "5.3.2.1",
              "title": "Measurement Methods"
            },
            {
              "number": "5.3.3",
              "title": "Efficacy Variables"
            },
            {
              "number": "5.3.3.1",
              "title": "Primary Variables"
            },
            {
              "number": "5.3.3.2",
              "title": "Key Secondary Variables"
            },
            {
              "number": "5.3.3.3",
              "title": "Additional Variables"
            }
          ]
        }
      ]
    }
  }
}